Biosimilars Marketing: Companies Must Find "Sweet Spot" Between Generic And Innovator Approach
Executive Summary
While biosimilars have yet to launch in the U.S., marketing executives are mulling over the challenges that lie ahead for commercialization.
You may also be interested in...
And Now For The Real Biosimilar Opportunity: Antibodies And Complex Biologics
With patents on blockbuster drugs – including Roche/Biogen Idec Inc.'s Rituxan (rituximab), Amgen Inc./Pfizer Inc.'s Enbrel (etanercept) and Roche's Herceptin (trastuzumab) – due to expire in key markets within the next three years, there's a renewed buzz around biosimilars as industry players seek to grab a share of this multi-billion dollar opportunity.
Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
The addition of the Phase III candidate to its portfolio positions Merck as a leader in the race to launch a low-cost version of a major rheumatoid arthritis drug.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.